Minimal Residual Disease Testing (eBook, PDF)

Current Innovations and Future Directions
Redaktion: Druley, Todd E.

• Format: PDF

Produktbeschreibung

This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD.

Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Springer International Publishing
• Seitenzahl: 197
• Erscheinungstermin: 15. November 2018
• Englisch
• ISBN-13: 9783319948270
• Artikelnr.: 54557971

Autorenporträt

Todd E. Druley, MD, PhD Associate Professor of Pediatrics, Genetics and Developmental Biology Director, Fellowship Program in Pediatric Hematology and Oncology Director, Pediatric Cancer Predisposition Program Washington University in St. Louis Department of Pediatrics Division of Hematology and Oncology Center for Genome Sciences and Systems Biology St. Louis, MO  USA

Inhaltsangabe

Introduction.- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma.- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.- Monitoring AML Response Using "Difference From Normal" Flow Cytometry.- ML-DS: A Unique Condition for Measurable Residual Disease Detection.- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.